Related Experiment Video

Updated: Apr 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Targeting the Pim kinases in multiple myeloma

N A Keane1, M Reidy2, A Natoni2

  • 1Apoptosis Research Centre, National University of Ireland Galway and Department of Haematology, Galway University Hospital, Galway, Ireland.

Blood Cancer Journal
|July 18, 2015
PubMed

Insights

Multiple myeloma (MM) treatment needs novel strategies. Targeting Pim-2, a kinase upregulated in MM, offers a promising therapeutic avenue by inhibiting cancer cell survival and bone destruction.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma (MM) is an incurable plasma cell malignancy.
  • Novel therapeutic strategies are essential to improve patient survival rates.
  • Pim kinases, particularly Pim-2, are overexpressed in hematological malignancies, including MM.

Purpose of the Study:

  • To investigate the role of Pim-2 in multiple myeloma pathogenesis.
  • To evaluate Pim-2 as a therapeutic target for MM.
  • To explore the potential of Pim inhibitors in MM treatment.

Main Methods:

  • Analysis of Pim kinase expression in MM.
  • Investigation of Pim-2's function in MM cell proliferation and survival.
  • Assessment of Pim-2's role in MM-related bone destruction.
  • Evaluation of Pim inhibitor activity in MM models.

Main Results:

  • Pim-2 is highly expressed in MM and upregulated by the bone marrow microenvironment.
  • Pim-2 promotes MM cell proliferation, survival, and bone destruction.
  • Pim kinases may also influence malignant cell trafficking, oncogenic signaling, and therapy resistance.
  • The Pim inhibitor LGH447 has demonstrated single-agent activity in MM.

Conclusions:

  • Pim-2 is a crucial therapeutic target in multiple myeloma.
  • Pim inhibition holds promise for improving MM treatment outcomes.
  • Combination therapies involving Pim inhibitors may enhance clinical benefit in MM.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K